Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer
Introduction
The sentinel node (SN) procedure is widely accepted as a reliable method for staging the axilla in breast cancer patients. The method is though time consuming and expensive. Since SN is only relevant in patients who have no signs of metastasis to the axillary lymph nodes (LNs), reliable preoperative assessment is becoming increasingly important.
Some standard texts,1 some international research protocols,2 and some national guidelines3, 4 use clinical palpation of the axilla as a criterion for whether the patient should be offered SN or not. That is to say, clinically palpable LNs are regarded as a contraindication for SN while a patient with non-palpable LNs may be offered SN.
However, many studies have shown that clinical assessment of axillary LNs is inaccurate.5, 6
We found it of interest to study two aspects of this problem:
- 1
How reliable is clinical axillary LN assessment in the hands of experienced breast surgeons?
- 2
Can the inaccuracy of the clinical assessment be related to LN size?
Section snippets
Patients and methods
The Breast Surgery Clinic, Horsholm Hospital, is a centralized breast care unit serving a population of 375,000. It is manned by 5 full-time specialist breast surgeons. The clinic has about 10,000 out-patient visits per year and treats about 350 women with primary breast cancer per year.7
Three hundred and one consecutive patients with newly diagnosed invasive breast cancer undergoing either axillary dissection or SN in the period from 1st June, 2003 to 31st June, 2004 were studied
Results
Of the 223 cases (72.6%) assessed as having non-palpable LNs, metastases were found in 90 cases. The negative predictive value was 59.6%. There were palpable LNs in 84 of 307 axillas (27.4%). In 52 cases (16.9%) the palpable LN was assessed as benign. Of these, 32 had metastases. The negative predictive value was 38.5%. In 32 cases (10.4%) the palpation revealed suspicious LNs. The diagnosis was confirmed in 27 of these cases. The positive predictive value was 84.4%. These differences were
Discussion
Clinical examination of the axilla is notoriously inaccurate.5, 6 This is the case also when the axillary palpation is done by experts. In a study from Memorial Sloan Kettering Cancer Center,5 only 77% of LNs which were highly suspicious at palpation had metastases. Our study confirms that even in the hands of specialist breast surgeons, the examination has little value. When the surgeons considered the axilla to be normal, they were wrong in 44% of cases. They were better at diagnosing
Conclusion
The message of our study is that clinical assessment of axillary LNs as a criterion for offering the SN procedure is of little value. This is the case even in the hands of highly specialized surgeons. We believe that the clinical assessment of the axilla should be supplemented with ultrasound examination and that fine needle aspiration cytology should be added if LNs are considered suspicious at ultrasound examination.
References (9)
- et al.
Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?
J Am Coll Surg
(2005) Analysis of surgical and diagnostic quality at a specialist breast unit
The Breast
(2006)- et al.
False-negative frozen section of sentinel lymph node biopsy for breast cancer
The Breast
(2004) - et al.
Preoperative axillary ultrasound scan: its accuracy in assessing the axillary nodal status in carcinoma breast
The Breast
(2002)
Cited by (56)
Is preoperative ultrasound of the axilla necessary in screen-detected breast cancer?
2020, European Journal of Surgical OncologyCitation Excerpt :The optimal preoperative staging of the axilla has been debated for a long time. Clinical examination is notoriously inaccurate as in approximately 40% of patients with clinically negative axilla metastatic deposits are found in SLN [6,7]. Moreover, about a quarter of patients with clinically suspicious axilla has negative lymph nodes on final pathology [8].
Value of Axillary Ultrasound after Negative Axillary MRI for Evaluating Nodal Status in High-Risk Breast Cancer
2019, Journal of the American College of SurgeonsThe influence of breast cancer subtypes on axillary ultrasound accuracy: A retrospective single center analysis of 583 women
2019, European Journal of Surgical OncologyCitation Excerpt :In this respect the need for an accurate preoperative staging method with excellent specificity and negative predictive value (NPV) for the axilla is important in order not to undertreat patients in the future. While clinical axillary staging by palpation is extremely unaccurate [6,7], AUS may provide more relevant information. Recently the largest analysis regarding accuracy of AUS demonstrated a 60% sensitivity with an 80% PPV and a 90% specificity with a 75% NPV [8].
Reducing harms from treatment. Sixteen years of surgery of the axilla for screen-detected breast cancers in Italy
2018, BreastCitation Excerpt :This minimally invasive technique allowed to abandon ALND without affecting outcome [4,5] and substantially reducing morbidity [6]. Physical examination, ultrasound, mammography and magnetic resonance are neither sensitive or reliable to ascertain the status of the axillary lymph nodes in invasive breast cancer, so surgical staging is generally still indicated, even in the setting of a clinically negative axilla, as the histology examination of removed lymph nodes is the most accurate method of assessing spread of the disease to these nodes [7,8]. The likelihood of axillary lymph node involvement increases as the size of the primary tumor increases, even in contemporary series [9,10].
Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells
2018, Human PathologyCitation Excerpt :Metastatic involvement of axillary LN is the single most important prognostic factor in BC. Exclusion and inclusion criteria are essential for diagnostic precision, accurate prediction, and overall improvement of patient care [15,16]. Although this is an exciting time for immunotherapy, we are still far from understanding the exact relationship between PD-L1 expression by TIL and cancer cells and other immunologic features of the breast tumor microenvironment.